←
Michael W. Straza, MD/PhD1,648 posts
Michael W. Straza, MD/PhD avatar

Michael W. Straza, MD/PhD

@WStraza

Radiation Oncologist @MCWRadOnc specializing in brain, liver and prostate cancer. Proud father, NPS enthusiast, and Chicago transplant All tweets are my own.

◷ Joined January 2019▧ 236 Photos and videos
Jeff Ryckman avatar
⟳ Michael W. Straza, MD/PhD retweeted
Jeff Ryckman@jryckman3·Jul 22

Thanks, Frank! I get so many calls from friends and family asking about focal therapy advertising. I’ve also personally salvaged more than 20 focal therapy failures, including one patient who now lives with a debilitating day-to-day outcome that would have been exceedingly unlikely in the absence of the focal therapy context. That’s why I’m so invested in pushing back on misinformation and encouraging patients and clinicians to wait for randomized trial data before embracing the marketing narrative.

Drew Moghanaki avatar
⟳ Michael W. Straza, MD/PhD retweeted
Drew Moghanaki@DrewMoghanaki·May 21

It’s time to revisit the value of nephrectomy for RCC and when it might actually be a better treatment.

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm 1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months. 2) 100% Cancer-Specific Survival 3) Grade 3 AEs remain at 10%

Post attachment
Daniel E Spratt avatar
⟳ Michael W. Straza, MD/PhD retweeted
Daniel E Spratt@DrSpratticus·Mar 11

Hence why people don’t trust science or MDs anymore. We have a doctor you posted likely paid saying they violated national guidelines for what payers deem experimental, we have biomedical news agencies funded by industry saying these devices are amazing for things they are not approved for, we have major medical meetings promoting these devices, we even have @nytimes articles saying how great these devices are. Yet reality is there is not a single well done multi center randomized trial with reasonable endpoints and good followup showing it is better than AS or RT. To be clear, none of this is targeting the Vanquish system. It is the whole field of ablative devices being used for cancer without being approved for cancer.

Milwaukee Brewers avatar
⟳ Michael W. Straza, MD/PhD retweeted
Milwaukee Brewers@Brewers·10 Aug 2025

COMEBACK COMPLETE!!!!!!!!!!!!!!!!!!!!!!!!!!!

0:33

ISAAAAAC WALKS IT OFF!!!!!!!!!!!

0:06
blange00 avatar
⟳ Michael W. Straza, MD/PhD retweeted
blange00@blange00·9 Jan 2025

Now tell me who the real MVP is

Post attachment
NRG Oncology avatar
⟳ Michael W. Straza, MD/PhD retweeted
NRG Oncology@NRGonc·17 Sep 2024

The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 will compare two schedules of stereotactic radiosurgery (SRS) for patients with intact brain metastases. @Rrkotecha Read more: ow.ly/7Paq50Tmfma

Post attachment
MR-Linac Consortium avatar
⟳ Michael W. Straza, MD/PhD retweeted
MR-Linac Consortium@mr_linac·23 Oct 2024

Our annual Technical and Clinical Abstract Awards will now honour two of our most dedicated colleagues. 🔬 The Technical Abstract Award is named after Prof. Jan Jacob Wouter Lagendijk 🏥 The Clinical Abstract Award is named after Dr. Christopher Schultz mrlconsortium.org

Post attachment
Stanislav (Stas) Lazarev, MD avatar
⟳ Michael W. Straza, MD/PhD retweeted
Stanislav (Stas) Lazarev, MD@StasLazarev·7 Aug 2024

⚡️Today FDA approved Vorasidenib for IDH-mutant low grade gliomas When patients ask you about this drug, make sure to inform them that ▶️ risk of tumor progression at 2 years is 49% with Vorasidenib (INDIGO trial) compared to 15% with chemoRT (RTOG 9802) ▶️tumors remain stable without any major progression in 83% of patients receiving Vorasidenib versus 88% receiving a sugar pill (INDIGO trial, Table S4) ▶️patients who do not receive standard chemoRT live 5.5 years shorter than those who do (RTOG 9802) ▶️Vorasidenib has never been compared to standard chemoRT in a rigorous clinical trial

#BreakingNews Today, the U.S. FDA approved the first targeted therapy for Grade 2 IDH-mutant #glioma – a relentless condition that hasn’t seen treatment advances in nearly 25 years. Learn more about this and Servier’s commitment to patients: ow.ly/yN8j50SRETU

1:35